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Background: Most hospitalized preterm infants receive antibiotics in the first days of
life to prevent or treat infections. Short-term, early antibiotic treatment may also prevent
the microbiota-dependent gut inflammatory disorder, necrotizing enterocolitis (NEC). It
remains a challenge to predict NEC, and a few early blood diagnostic markers exist.
Using preterm pigs as model for infants, blood parameters and plasma proteins affected
by early progression of NEC were profiled in preterm pigs subjected to oral, systemic, or
no antibiotics after preterm birth.
Methods: Preterm newborn pigs were treated with saline (CON) or antibiotics (ampicillin,
gentamicin, and metronidazole) given enterally (ENT) or parenterally (PAR), and fed
formula for 4 days to induce variable microbiome-dependent sensitivities to NEC. The gut
was collected for macroscopic scoring of NEC lesions and blood for hematology, blood
biochemistry, and LC/MS-based plasma proteomics. Statistical modeling was applied to
detect plasma proteins affected by NEC and/or antibiotics.
Results: Analyzed across different antibiotic regimens, NEC progression was
associated with altered blood parameters and abundance of 89 plasma proteins that
were functionally involved in extracellular membrane destruction, lipid metabolism,
coagulopathy, and acute phase response. Large NEC-related changes were observed in
abundance of RBP4, FGA, AHSG, C5, PTPRG, and A-1-antichymotrypsin 2, indicating
potential serving as early markers of NEC. Conversely, antibiotic treatment, independent
of NEC, affected only 4 proteins with main differences found between ENT and CON pigs.
Conclusion: Early postnatal development of NEC lesions is associated with marked
plasma protein changes that may be used for early NEC diagnosis.
Keywords: necrotizing enterocolitis (NEC), antibiotics, proteomics, ECM, lipid metabilism, immunity
Jiang et al. Early Protein Markers of Necrotizing Enterocolitis
INTRODUCTION
Necrotizing enterocolitis (NEC) is a common gastrointestinal
tract (GIT) disease with high mortality in preterm infants
(1). Besides the gut symptoms, such as elevated permeability,
immune cell infiltration, and tissue inflammatory response (1),
NEC is closely related to systemic inflammation, potentially
leading to injury of organs distant to the GIT, such as the
brain and lungs (2). NEC-associated systemic inflammation
includes changes in blood cell composition, such as leukopenia,
monocytopenia, thrombocytopenia, and/or suppression of
erythropoiesis, (3) and in plasma levels of pro-inflammatory
cytokines (IL-6 and IL-8) (4) and multiple immune-related
proteins, such as C-reactive protein (CRP), procalcitonin,
and serum amyloid-A (SAA). All these are potential markers
for NEC (5), but it remains difficult to differentiate NEC
from systemic inflammatory conditions, like sepsis, which
may be associated with NEC or occur independently.
There is a need to better understand how gut inflammatory
conditions may affect plasma proteins that could serve to
predict NEC early, thus allowing timely NEC prevention and
treatment (6).
The gut bacterial colonization in early life is involved in
NEC. Dyscolonization with a few (pathogenic) strains may
predispose to both NEC and systemic infections (7). Early
antibiotic treatment, commonly used to treat or prevent sepsis
and infection (8), affects the gut microbiome, and a less diverse
gut microbiome is associated with NEC in preterm infants
(9). Prolonged antibiotic treatment increases the incidence of
NEC and sepsis (10, 11), but short-term systemic antibiotic
treatment, given to about 90% of very preterm infants, is
recently shown to be associated with less NEC in a survey
from 13 NICUs across the world (12). This supports findings
from previous studies demonstrating protection against NEC
after prophylactic enteral antibiotics in infants (13) and preterm
pigs (6, 14). In these studies, the enteral antibiotic treatment
reduced gut bacterial load and diversity, and prevented structural
and functional damage, hypoxic stress, and immune-related
DNA methylation changes in the small intestinal tissue (6, 15).
As reported earlier, NEC lesions observed in such preterm
formula-fed pigs on day 5 of life are generally evident by
macroscopic tissue inspection without any previous clinical
signs of NEC, e.g., abdominal distention, bloody stools,
apnea or lethargy, hence, representing the early phase of
clinical NEC (6). Of note, the enteral antibiotic treatment
also affected the systemic innate immunity (16), indicating
that the antibiotic treatment may affect systemic parameters
including plasma proteins, independent of the NEC effects.
Among different biofluids available for disease biomarkers, blood
remains the sample of choice due to its easy availability and
its potential to reflect pathophysiological changes in a variety
of organs.
On this background, we hypothesize that early postnatal
progression of NEC, as detected in preterm pigs fed formula,
induces plasma proteome changes reflecting systemic effects
of early NEC. Considering the variable, but frequent, use of
antibiotic treatment for preterm infants immediately after
birth, and the critical role of the gut microbiome in NEC,
preterm newborn pigs were exposed to either no antibiotics,
systemic or enteral antibiotics in clinically relevant doses,
creating a range of antibiotic-dependent NEC sensitivities.
NEC-related systemic responses in these pigs were assessed
by hematology, blood biochemistry, and plasma protein
profile by mass spectrometry (MS)-based proteomics. Gene
expression of selected plasma proteins affected by NEC or
the antibiotic treatment was assessed in the liver and small
intestinal tissue.
MATERIALS AND METHODS
Animal Procedure and Antibiotic Treatment
Delivery, rearing, feeding, and antibiotic treatment were carried
out as previously described (6). In brief, 47 preterm pigs were
delivered from three sows (Large White × Danish Landrace ×
Duroc) by cesarean section on day 106 (90–92%) of gestation
(day 1). After being fitted with umbilical arterial catheters
(infant feeding tube 4F; Portex, Kent, UK) and orogastric
feeding tubes (6F Portex), these pigs were reared in temperature-
and oxygen-regulated incubators. A group of pigs was given
antibiotics through the umbilical catheter (PAR, n = 17), the
other 15 pigs received antibiotics via the orogastric tube (ENT,
n = 15), and the remaining pigs received saline, serving as
untreated controls (CON, n = 15). The antibiotics used were
ampicillin (30 mg/kg BW, 3 times daily), gentamicin (2.5 mg/kg
BW, twice daily), and metronidazole (10 mg/kg BW, 3 times
daily), specifically formulated for enteral and parenteral use. The
antibiotic treatment started immediately after the enteral feeding
started on day 1 until the euthanasia on day 5. All pigs were given
both parenteral nutrition (4 mL/kg/h in the first 24 h, gradually
increasing to 6–8 mL/kg/h) and minimal enteral nutrition (3
mL/kg every 3 h) on days 1 and 2, before being shifted to full
enteral feeding (15 mL/kg every 3 h) on day 3 until the end of
the experiment on day 5. Formulations of both parenteral and
enteral nutrition are provided as Supplementary Table 1.
On day 5, under anesthesia, all pigs were euthanized by
an overdose of pentobarbital after blood sampling through
an intracardiac puncture. Whole blood was collected for cell
counting, and EDTA-treated plasma was saved for blood
biochemistry and proteomic analysis. As previously described
(14), each pig was given an oral bolus (15 mL/kg BW) of a
solution containing 5% lactulose and 5% mannitol 3 h before
the planned euthanasia, and a urine sample was collected via
cystocentesis at euthanasia. Prior to the oral bolus, individual
pigs randomly underwent a 2 to 4 h fasting period, and received
the last enteral feeding 60min before the urine collection
following euthanasia. Intestinal permeability was assessed by
the urinary ratio of lactulose and mannitol. The GIT of each
piglet was collected, and five regions, namely, the stomach,
proximal, middle, and distal small intestines, and colon, were
separately evaluated for macroscopic NEC severity using a
validated NEC scoring system as follows: (1) absence of
macroscopic hemorrhage, edema, or mucosal abnormality; (2)
local hyperemia; (3) hyperemia, extensive edema and local
hemorrhage; (4) extensive hemorrhage; (5) local necrosis and
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pneumatosis intestinalis; and (6) extensive transmural necrosis
and pneumatosis intestinalis (14). Themaximal NEC score across
these five regions was recorded as the NEC score of the pig to
indicate the overall NEC severity.
Blood cell counting was conducted on an Advia 2120i
Hematology System (Siemens, Munich, Germany). Plasma
biochemistry was analyzed using Advia 1800 Chemistry systems
(Siemens, Erlangen, Germany). The study was approved by
the Danish National Committee of Animal Experimentation
(no. 2014-15-0201-00418).
LC/MS-Based Plasma Proteomics
The preparation of a protein sample was performed using
a filter-aided protocol, as previously described (17). Briefly,
protein concentration in the plasma samples was determined on
a NanoDrop Spectrophotometer (Thermo Scientific, Waltham,
MA, USA). Plasma sample containing 100 µg protein was
transferred onto an Amicon Ultra centrifugal filter (10 kDa,
0.5mL, Millipore, Søborg, Denmark), and mixed with a buffer
containing sodium deoxycholate (5%) and triethylammonium
bicarbonate (50 mmol/L, pH 8.0). Protein was reduced by TCEP
solution [0.01 mol/L, 1:50 (v/v)], alkylated by chloroacetamide
[0.5 mol/L, 1:50 (v/v)], and digested by trypsin (Promega,
1 µg/100 µg protein, 37◦C overnight) inside the spin filter
with a centrifuge step (14,000 × g for 15min) in between.
Tryptic peptides were recovered by another step of centrifugation
and purified by phase extraction using ethyl acetate acidified
by trifluoroacetic acid (1%, v/v). Vacuum-dried peptides were
suspended in a solution of 2% acetonitrile, 0.1% formic acid, and
0.1% trifluoroacetic acid, and applied onto a Dionex RSLC UPLC
System (Thermo Scientific) coupled to a Q-Exactive HF Hybrid
Quadrupole-Orbitrap Mass Spectrometer (Thermo Scientific).
Five micrograms of peptide was injected onto a 2 cm reverse-
phase C18 material-trapping column and separated on a 50-
cm analytical column (Acclaim PepMap100, 75µm ID, 100 Å,
Thermo Scientific) with both columns kept at 40◦C. Elution
gradient at a constant flow rate of 300 nl/min started with a
mixture of water (97.9%) and acetonitrile (2%) containing 0.1%
formic acid, then increased to 30% acetonitrile in 225min. Mass
spectrometric data were obtained in positive ionization mode in
a data-dependent acquisition (DDA) fashion with survey spectra
and isolation/fragmentation spectra alternating using a Top12
method. Selected peptides were excluded from reanalysis for 30 s.
Protein annotation and quantification based on mass spectra
of peptides were carried out using MaxQuant (1.5.2.8) (18)
against the Uniprot reference database with isoforms (Sus scrofa,
UP000008227, last modified 2016-08-02). Detection of at least
two unique peptides per protein and protein being present in
at least 70% of the samples in each group were required for
protein annotation and quantification. Protein abundance data
were normalized and two-based logarithm transformed using
the Perseus software (version 1.2.0.17) (19), then aligned with
protein identities and grouping information, such as treatment,
litter (sow), NEC score, and sex, and exported into R (version
3.4.1) (20) integrated with R Studio (version 3.1.18) (21) for
data analysis. The MS proteomics data are available at the
ProteomeXchange Consortium (http://www.proteomexchange.
org/) with the data set identifier PXD015938.
RT-qPCR of Hepatic and Distal Small
Intestinal Genes
To balance the effect of litter and sex for treatment comparisons,
one pig of each sex from each litter was selected for each
treatment group. A random number selection method was
used to choose the sample when more than one pig was
eligible for each litter, sex, and treatment. Two more pigs
(one male and one female) were randomly selected from any
two treatment groups with eligible candidates, resulting in
total 24 pigs selected (n = 8 in each group) for the RT-
qPCR analysis. The NEC scores of the selected pigs were not
significantly different from those of the entire groups (χ2 test,
P = 0.90). Transcription of selected genes in the liver and distal
small intestine was determined by RT-qPCR, using predesigned
primers (sequences listed in Supplementary Table 3). Briefly,
total RNA in the tissue homogenate was isolated with RNeasy
Lipid Tissue Mini Kit (Qiagen, Copenhagen, Denmark). RT-
qPCR was performed using QuantiTect SYBR Green PCR Kit
(Qiagen) on a LightCycler 480 (Roche, Hvidovre, Denmark).
Levels of target gene were normalized to that of the housekeeping
gene, HPRT1 (22), before further statistical analysis.
Data Analysis
Univariate analysis was applied to hematologcial, blood
biochemical, and proteomic data. A linear mixed-effect model
with the antibiotic treatment (CON, PAR, and ENT), NEC score
in continuous mode, and sex of the pig as fixed-effect factors,
while litter (sow) being a random-effect factor, was fitted to each
parameter (hematology, blood biochemistry, and proteomics)
using the nlme package (23). Variance Inflation Factor (VIF) of
the model was tested by the vif function to evaluate the possible
colinearity of treatment and NEC score. A VIF larger than
2.5 indicated existence of colinearity, and the model would be
rejected. The effect of treatment or NEC was tested by comparing
this model with another model without treatment or NEC score
as factor, respectively. The difference between the treatment
levels was tested in a pairwise fashion by the Tukey post hoc test
(package multcomp). The regression coefficient of NEC severity
was used to show the effect of NEC severity on each parameter.
To control the type I error of analysis of the proteomics data,
the P-value obtained was further adjusted by false discovery rate
(FDR, α = 0.2) into q-value using the multtest package (24).
Proteins with a value of q ≤ 0.10 in any comparisons between
the treatment groups were selected for functional assignment.
To explore associations between proteins revealed by the
proteomic analysis, their abundance was applied to Spearman
correlation analysis in pairwise fashion. Correlations with the
absolute value of Spearman’s r <0.7 were manually clustered
and imported into AutoAnnotate (Version 1.3.3) (25) based
on Cytoscape (Version 3.8.0) (26) to generate a protein
correlation network.
Results from RT-qPCR were analyzed using Student’s
t-test, and a two-tailed P < 0.05 was considered as
statistically significant.
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RESULTS
Clinical Data, Hematology, and Blood
Biochemistry
A total of 47 pigs out of the initial 64 pigs were included
in this study, while 17 pigs dying within the first 2 days
from immaturity-related complications (respiratory distress
and immaturity of lungs) were excluded. Hematological and
plasma biochemical parameters of the pigs included for the
proteomic analysis are listed in Table 1, and NEC scores of
each treatment group are listed in Supplementary Table 2 and
Supplementary Figure 1. NEC severity of the small intestine
and colon was scored according to their NEC lesions, and
representative images are displayed in Figure 1. Lower NEC
scores were found in ENT pigs, relative to both PAR and CON
pigs (two-tailed t-test, P < 0.05). PAR pigs also had lower NEC
score than CON pigs (P < 0.05). Regardless of NEC, significantly
lower monocyte numbers (absolute counts or relative percentage,
both P < 0.05) found in the antibiotic groups (PAR or ENT),
had no significant difference between the two groups. ENT pigs
had the lowest number of neutrophils (P < 0.05, ENT vs. CON).
The antibiotic treatment tended to reduce levels of total plasma
protein (PAR vs. CON, P < 0.05; ENT vs. CON, P = 0.08) and
albumin (PAR vs. CON, P = 0.05).
NEC severity, as indicated by NEC scores, negatively affected
the numbers of immune cells (total white blood cells, neutrophils,
lymphocytes, and monocytes) (Table 1). Conversely, blood
biochemical parameters reflecting liver (dys)functions increased
with increasing NEC score (ALP, ALT, bilirubin, AST, and GGT,
all Ps < 0.05). Furthermore, NEC severity scores negatively
affected the cholesterol, carbamide and calcium levels (all Ps
< 0.05) (Table 1). Intestinal permeability, as indicated by the
ratio of urinary levels of lactulose over mannitol, increased with
increasing NEC severity (P < 0.01) (Table 1).
Plasma Proteomics
In total, 303 plasma proteins were successfully annotated.
Information of proteins with differential abundance, including
UniProt ID, gene name, protein name, and abundance in each
antibiotic treatment group or regression coefficient of NEC
severity, is listed in functional groups in Table 2. None of the
statistical models, testing the effect of the antibiotic treatment
and NEC, had a VIF above 2.5 indicating that keeping both
treatment and NEC severity in these models does not inflate
the variance; thus, testing the effect of both factors is reliable.
Results showed that 90 proteins were significantly affected (q
≤ 0.10) by either the antibiotic treatment or NEC. Among
the differential proteins, only four proteins, namely, serpin,
a6 and a8, angiotensinogen, and complement factor I (CFI),
were significantly affected by the antibiotic treatment, with
changes mainly observed between ENT and untreated control
pigs (q ≤ 0.10), except for CFI (ENT vs. PAR, q = 0.08). In
contrast, increasing NEC score was associated with changed
abundance of 89 plasma proteins. These proteins are involved
in several biological processes, including extracellular matrix
(ECM) homeostasis, lipid metabolism, coagulopathy, innate
immunity, and cytoskeleton. Direction of change in protein levels
is summarized in Figure 2.
Among the ECM-related proteins, all 11 proteins showed
decreased abundance with increasing NEC severity. Multiple
apolipoproteins, including APOA4, APOC2, APOE, APOD,
APOC3, ApoN, and proteins related to lipoprotein metabolism
(PON1, SAA, RBP4, Transthyretin, PCKS9, PAF-AH, and
PLTP) were affected in abundance in response to increasing
NEC score. As the NEC score increased, antithrombin III
(SERPINC1), PROS1, and factor V decreased, while fibrinogen-
α-chain, histidine-rich glycoprotein (HRG), and hyaluronan-
binding protein 2 (FSAP), all involved in inflammation-
related coagulopathy, showed increased abundance. Abundance
of “positive” acute phase proteins, including angiotensinogen,
ceruloplasmin, inter-α-trypsin inhibitor, heavy chain H4 (ITI
heavy chain H4), lipopolysaccharide-binding protein (LBP),
and α-1-antichymotrypsin 2, increased with increasing NEC
severity, while “negative” acute phase proteins, including α-2-
HS-glycoprotein, albumin, protein AMBP, carboxypeptidase-N-
catalytic chain (CPN), ITI heavy chain H2, and transferrin,
decreased. Plasma C2, C3, C5a, C6, CFI, and C1inh increased
as NEC severity increased, while plasma C1r, C4a, α-, β-, and
γ-subunits of C8, CD55, and vitronectin all decreased.
Multiple correlations were found among the three major
protein clusters relating to acute phase response, complement
response, and coagulopathy (Figure 3, all Spearman’s r ≥
0.7), which, together, constituted the systemic inflammation
pertaining to NEC. Besides, correlations were also found between
proteins involved in lipid metabolism and the aforementioned
three protein clusters (Figure 3, all Spearman’s r ≥ 0.7),
indicating potential interplays between systemic inflammation
and lipid metabolism in NEC.
Gene Expression
As shown in Figure 4, transcription of selected genes related to
lipid metabolism was tested in the liver. For easier visualization,
pigs were grouped into three groups according to their NEC
score. Liver PON1 levels tend to decrease in the severe NEC
group (P < 0.05) (Figure 4A). However, transcription levels
of PSCK9, HRG, and PROS1 showed no significant differences
among groups with different NEC severity (Figures 4B–D).
Plasma Abundance and Liver Transcription
of CBG
Plasma levels of CBG were significantly higher in the antibiotic-
treated groups (both P < 0.05) (Figure 5A), while limited effect
related to NEC severity was observed (Figure 5C). In contrast to
its plasma level, transcription level in the liver of CBG was lower
in the antibiotic-treated groups (both P < 0.05) (Figure 5B),
while no effect of NEC was observed (Figure 5D).
DISCUSSION
Using preterm pigs as a model for preterm infants, with
or without clinically relevant antibiotic treatments, multiple
hematological and plasma proteomic markers were affected by
NEC severity. In contrast, the antibiotic treatment itself affected
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TABLE 1 | Hematology and blood biochemistry.
Abundancea by treatment P-value NEC severity
CON PAR ENT PAR- CON ENT- CON ENT- PAR Coefficientb P-value
HEMATOLOGY
WBC (109/L) 2.3 ± 0.4 2.2 ± 0.2 2.2 ± 0.2 0.54 0.17 0.56 −0.31 <0.01
Neutrophils (109/L) 0.80 ± 0.21 0.72 ± 0.09 0.59 ± 0.06 0.63 0.04 0.13 −0.13 0.02
Lymphocytes (109/L) 1.31 ± 0.14 1.38 ± 0.12 1.54 ± 0.12 0.94 0.97 1 −0.16 0.01
Monocytes (109/L) 0.11 ± 0.03 0.06 ± 0.01 0.06 ± 0.01 0.01 <0.01 0.28 −0.02 0.01
Basophils (109/L) 0.01 ± 0.00 0.01 ± 0.00 0.01 ± 0.00 0.72 0.20 0.52 <0.01 0.46
Eosinophils (109/L) 0.02 ± 0.00 0.01 ± 0.00 0.01 ± 0.00 0.38 0.26 0.88 <0.01 0.78
Neutrophils (%) 31.4 ± 3.6 31.0 ± 2.6 26.3 ± 2.0 0.97 0.27 0.11 −0.69 0.54
Lymphocytes (%) 61.0 ± 4.0 63.5 ± 2.5 68.6 ± 2.3 0.95 0.10 0.10 0.77 0.52
Monocytes (%) 4.5 ± 0.6 3.0 ± 0.3 2.7 ± 0.5 0.03 0.02 0.82 −0.10 0.63
Basophils (%) 0.5 ± 0.1 0.4 ± 0.1 0.3 ± 0.0 0.95 0.97 1 0.05 0.16
Eosinophils (%) 0.6 ± 0.2 0.4 ± 0.1 0.4 ± 0.1 0.53 0.74 0.98 0.04 0.43
Erythrocytes (1012/L) 4.0 ± 0.2 4.0 ± 0.2 4.0 ± 0.2 0.79 0.77 0.99 −0.06 0.38
Hemoglobin (mmol/L) 4.9 ± 0.2 4.9 ± 0.2 4.9 ± 0.2 0.77 0.80 1 −0.06 0.49
Hematocrit (%) 26.4 ± 1.2 26.2 ± 1.0 26.5 ± 1.1 0.72 0.82 1 −0.32 0.51
MCV (fl) 65.4 ± 0.9 66.0 ± 0.5 66.7 ± 0.6 0.80 0.69 0.95 −0.12 0.66
MCHC (g/dl) 18.5 ± 0.1 18.6 ± 0.1 18.4 ± 0.1 0.88 0.71 0.35 −0.01 0.77
Thrombocytes (109/L) 137.2 ± 15.2 124.9 ± 18.7 106.9 ± 18.3 0.96 0.34 0.36 −11.4 0.11
MPV (fl) 8.5 ± 0.4 8.1 ± 0.3 8.3 ± 0.2 0.35 0.38 0.98 −0.17 0.20
MPC (g/dl) 209.6 ± 4.2 213.4 ± 4.1 217.3 ± 4.2 0.93 0.19 0.22 2.5 0.16
BLOOD BIOCHEMICAL PARAMETERS
Total protein, g/L 29.5 ± 0.7 27.6 ± 0.5 27.5 ± 0.4 0.03 0.08 1 0.01 0.97
Albumin, g/L 12.5 ± 0.4 11.6 ± 0.3 11.6 ± 0.2 0.05 0.15 0.99 <0.01 0.93
ALT, U/L 19.9 ± 1.5 20.2 ± 1.9 17.5 ± 0.6 0.77 0.94 0.96 1.4 0.01
AST, U/L 46.1 ± 10.8 93.8 ± 36.2 55.6 ± 30.1 0.19 0.38 0.99 22.8 0.03
ALP, 103 U/L 3.1 ± 0.3 2.8 ± 0.2 2.6 ± 0.3 0.89 0.95 1 0.16 0.10
GGT, U/L 26.9 ± 4.1 25.9 ± 4.0 21.7 ± 2.2 0.86 0.45 0.70 3.3 0.01
Bilirubin, µmol/L 2.0 ± 0.7 1.1 ± 0.4 0.5 ± 0.1 0.47 0.87 0.87 0.62 <0.01
Total cholesterol, mmol/L 2.4 ± 0.1 2.4 ± 0.2 2.6 ± 0.1 0.79 0.55 0.86 −0.14 <0.01
Urea, mmol/L 10.3 ± 0.7 10.1 ± 0.7 10.0 ± 1.0 0.43 0.08 0.48 −0.69 0.03
Creatinine, µmol/L 56.0 ± 3.5 56.2 ± 3.0 47.0 ± 1.6 0.95 0.19 0.08 0.05 0.88
Creatine kinase, U/L 166.1 ± 33.4 317.2 ± 95.3 224.4 ± 109.8 0.25 0.47 0.98 48.2 0.15
Iron, µmol/L 6.3 ± 1.0 5.3 ± 0.5 8.0 ± 0.9 0.87 0.57 0.28 −0.25 0.53
Ionized phosphate, mmol/L 1.2 ± 0.1 1.4 ± 0.2 1.2 ± 0.1 0.19 0.30 1 0.14 0.01
Ca, mmol/L 3.0 ± 0.0 3.0 ± 0.0 3.0 ± 0.0 0.44 0.70 0.97 −0.03 0.03
Mg, mmol/L 0.9 ± 0.0 0.9 ± 0.0 0.9 ± 0.0 0.38 0.54 1 0.02 0.28
Na, mmol/L 158.1 ± 1.4 157.9 ± 1.1 161.0 ± 2.0 0.96 0.67 0.47 −0.30 0.70
K, mmol/L 4.5 ± 0.1 4.9 ± 0.5 5.6 ± 1.3 0.84 0.23 0.42 0.46 0.22
INTESTINAL PERMEABILITY
Lactulose/mannitol ratio (10−2) 8.8 ± 3.3 9.5 ± 2.7 3.8 ± 1.3 0.55 <0.01 0.01 −2.4 0.02
aData are shown as mean ± SEM. bRegression coefficient from the linear mixed-effect model indicating the effect of NEC severity. CON, no antibiotic treatment; PAR, parenteral
antibiotics administered; ENT, enteral antibiotics administered.
WBC, total leukocytes; MCV, mean corpuscular volume; MCHC, mean corpuscular hemoglobin concentration; MPV, mean platelet volume; MPC, mean platelet component; ALP, alkaline
phosphatase; ALT, alanine transaminase; AST, aspartate aminotransferase; GGT, γ-glutamyltransferase.
much fewer parameters. Due to the fact that the antibiotics, as
a treatment for NEC, had a significant effect on NEC scores (P
< 0.001, linear mixed-effect model, Supplementary Table 1 and
Supplementary Figure 1), it is difficult, pathophysiologically, to
fully separate the effects of NEC from that of the antibiotic
treatment. However, by using NEC scores as continuous data, our
statistical analyses showed that NEC severity, not the antibiotic
treatment, was the key factor driving changes to plasma proteins.
Besides, bacteremia, the presence of bacteria in the blood, may
itself trigger changes in plasma proteins (27). In our previous
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FIGURE 1 | Representative images of the small intestine (A) and the colon (B) with or without necrotizing enterocolitis (NEC) lesions. The macroscopic NEC severity
was evaluated using a scoring system as follows: 1, absence of macroscopic hemorrhage, edema, or mucosal abnormality; 2, local hyperemia; 3, hyperemia,
extensive edema, and local hemorrhage; 4, extensive hemorrhage; 5, local necrosis and pneumatosis intestinalis; and 6, extensive transmural necrosis and
pneumatosis intestinalis.
publication on the same set of pigs, bacteremia, detected by
blood-agar culture, was documented in CON (9 out of 17) and
PAR (2 out of 16) pigs, but was absent in all ENT pigs at
euthanasia (16), indicating that NEC in 5 day-old preterm pigs
is generally associated with bacteremia. Consequently, it is not
possible in this study, like in studies on infants, to separate
the plasma proteome effects of NEC lesions in the gut from
the effects of NEC-associated systemic inflammation following
bacterial translocation. This is similar to the situation in preterm
infants with NEC where systemic effects are inevitably the
combined result of variable gut lesions, antibiotics treatment, and
systemic bacteremia, making it difficult to identify NEC-specific
systemic biomarkers.
Among the hematological parameters, absolute cell numbers
of neutrophils, lymphocytes, and monocytes, but not their
relative proportions, decreased with increasing NEC severity,
shown as negative regression coefficients, confirming the
observations in infants (3), although no eosinophilia or
thrombocytopenia was observed in the pigs. These responses
may be partly related to the altered levels of the liver function-
related enzymes (ALT, AST, and GGT), representing a joint
systemic inflammatory response associated with NEC. Increment
in the intestinal permeability found here may have initiated this
systemic inflammation by allowing bacteria and their toxins to
enter into the circulation. This is underscored by our previous
finding of the presence of bacteria in the blood of CON and PAR
pigs showing NEC lesions and absence of systemic bacteria in
ENT pigs, which were essentially NEC free (16). This bacteremia
would, in turn, cause changes in various blood parameters.
The observed NEC-associated changes in the blood parameters,
including the plasma proteins, may, therefore, be the combined
response to microbiota-dependent NEC lesions in the gut and
their associated systemic effects in the blood and organs distant
to the gut, e.g., liver or kidney.
Disruption of the intestinal ECM, together with intestinal
inflammation and immune cell infiltration, is closely associated
with NEC pathogenesis (28). Disturbed ECM homeostasis
was indicated by a change of a matrix metalloproteinase
(MMP-2), an MMP-activating thioredoxin (QSOX1) (29), a
product of MMP-mediated cleavage (COL6A3), integrin-α2
and vitronectin (connecting ECM and epithelial cells) and
cadherin-11, a cell-adhesion protein. The majority of ECM-
associated proteins in plasma were decreased in abundance with
increasing NEC severity. However, such proteins may change
differently in plasma and in the gut tissue during NEC as
intestinal expression of MMP-2,−9, TIMP-1,−2 were reported
being elevated in human NEC (30), contrasting our findings in
plasma. Similarly, desmoglein-2, a component of desmosome and
associated with perturbed epithelial barrier function, increased
with increasing NEC severity, but was reduced in the intestinal
tissue of patients with IBD (31). In NEC, elevated intestinal
expression of ECM-associated proteins, especially MMP-2, −9
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TABLE 2 | Proteins with differential abundance by NEC or the antibiotic treatment.
Uniprot ID Gene Protein Abundancea by treatment q-value NEC severity
CON PAR ENT PAR- CON ENT- CON ENT- PAR Coefficientb q-value
PROTEINS AFFECTED BY ANTIBIOTICS TREATMENT
F1RG45 AGT Angiotensinogen preproprotein 29.2 ± 0.2 29.4 ± 0.2 29.5 ± 0.2 0.77 0.08 0.99 0.32 <0.01
CBG Serpina6 Corticosteroid-binding globulin 26.7 ± 0.1 26.9 ± 0.2 27.3 ± 0.1 0.97 0.08 0.12 0.07 0.18
F1S133 CFI Complement factor I 28.1 ± 0.1 27.9 ± 0.1 28.3 ± 0.1 0.86 0.39 0.06 0.05 0.10
F1SCD0 LOC100153899 Serpin A3-8 32.9 ± 0.2 33.2 ± 0.2 33.2 ± 0.1 0.45 0.06 0.99 0.23 <0.01
PROTEINS AFFECTED BY NEC
EXTRACELLULAR MATRIX HOMEOSTASIS
F1RFU7 CDH11 Cadherin-11 isoform X1 22.6 ± 0.2 22.8 ± 0.2 23.0 ± 0.1 0.97 0.98 0.99 −0.19 0.05
F1S021 COL5A1 Collagen α-1(V) chain 24.4 ± 0.1 24.7 ± 0.2 24.9 ± 0.2 0.97 0.98 0.99 −0.21 0.02
I3LUR7 COL6A3 Collagen type VI α 3 chain 26.6 ± 0.1 26.9 ± 0.1 27.1 ± 0.1 0.97 0.96 0.99 −0.12 0.05
F1RTT3 COL9A1 Collagen α-1(V) chain 22.8 ± 0.2 23.0 ± 0.3 23.3 ± 0.2 0.97 0.98 0.99 −0.26 0.02
F1S902 COMP Cartilage oligomeric matrix
protein
24.3 ± 0.1 24.2 ± 0.1 24.6 ± 0.1 0.97 0.98 0.99 −0.14 0.02
I3LC64 ECM1 Extracellular matrix protein 1 25.3 ± 0.2 25.3 ± 0.2 25.3 ± 0.2 0.97 0.78 0.99 −0.20 0.02
F1SQL2 EFEMP1 EGF containing fibulin
extracellular matrix protein 1
23.2 ± 0.1 23.5 ± 0.1 23.5 ± 0.1 0.97 0.98 0.99 −0.12 0.06
F1SMF4 ITGA2 Integrin subunit α-2 22.4 ± 0.1 22.8 ± 0.2 23.1 ± 0.1 0.97 0.96 0.99 0.16 0.03
F1RF11 MMP2 72 kDa type IV collagenase 22.9 ± 0.2 23.4 ± 0.2 23.8 ± 0.1 0.87 0.51 0.99 −0.17 0.06
F1S682 QSOX1 Sulfhydryl oxidase 28.1 ± 0.1 28.1 ± 0.1 28.2 ± 0.1 0.97 0.98 0.99 −0.06 0.10
VTNC VTN Vitronectin 25.5 ± 0.3 25.8 ± 0.4 26.5 ± 0.2 0.97 0.98 0.99 −0.27 0.06
LIPID METABOLISM
APOA4 SAA2 Serum amyloid A protein 32.0 ± 0.1 32.3 ± 0.1 32.5 ± 0.1 0.64 0.59 0.99 −0.10 0.01
D3Y264 APOA4 Apolipoprotein A-IV 28.4 ± 0.2 28.9 ± 0.2 28.7 ± 0.2 0.89 0.98 0.99 −0.24 0.01
APOC3 APOC2 Apolipoprotein C-II 31.4 ± 0.2 31.4 ± 0.2 31.9 ± 0.1 0.97 0.98 0.99 −0.26 <0.01
F1SQX9_ APOC3 Apolipoprotein C-III 29.3 ± 0.2 29.3 ± 0.2 29.5 ± 0.2 0.97 0.98 0.99 −0.26 0.01
APOE APOD Apolipoprotein D 30.4 ± 0.1 30.3 ± 0.1 30.6 ± 0.1 0.97 0.98 0.99 −0.09 0.09
Q68RU1 APOE Apolipoprotein E 24.6 ± 0.4 24.6 ± 0.3 24.8 ± 0.3 0.97 0.75 0.99 0.30 0.07
Q4Z8N7 ApoN Ovarian and testicular
apolipoprotein N
24.9 ± 0.2 25.3 ± 0.2 25.6 ± 0.1 0.97 0.98 0.99 −0.20 0.02
I3LGB2 PAF-AH Platelet-activating factor
acetylhydrolase
24.7 ± 0.1 24.6 ± 0.2 24.8 ± 0.1 0.97 0.98 0.99 −0.19 0.01
F1SC57 PCSK9 Proprotein convertase
subtilisin/kexin type 9
24.2 ± 0.1 24.2 ± 0.1 24.3 ± 0.2 0.97 0.98 0.99 −0.11 0.06
F1SFA1 PLTP Phospholipid transfer protein 24.8 ± 0.1 24.9 ± 0.2 25.2 ± 0.1 0.97 0.98 0.99 −0.16 0.03
RET4 PON1 Paraoxonase 1 27.2 ± 0.1 26.9 ± 0.2 27.4 ± 0.1 0.42 0.97 0.99 −0.19 0.01
F1S9B9 RBP4 Retinol-binding protein 4 23.4 ± 0.6 23.7 ± 0.9 21.6 ± 0.9 0.97 0.98 0.99 0.84 0.03
TTHY TTR Transthyretin 31.9 ± 0.1 32.0 ± 0.1 32.1 ± 0.1 0.97 0.98 0.99 −0.08 0.06
COAGULOPATHY
FA5 F5 Coagulation factor V 27.9 ± 0.2 27.9 ± 0.2 28.2 ± 0.1 0.97 0.98 0.99 −0.22 <0.01
FIBA FGA Fibrinogen-α-chain 28.5 ± 0.6 28.2 ± 0.6 27.0 ± 0.4 0.97 0.98 0.99 0.62 0.02
F1S5J5 HABP2 Hyaluronan binding protein 2 23.4 ± 0.1 23.3 ± 0.1 23.5 ± 0.1 0.97 0.43 0.99 0.08 0.10
F1SFI5 HRG Histidine-rich glycoprotein 31.0 ± 0.2 31.4 ± 0.1 31.2 ± 0.1 0.51 0.43 0.99 0.13 0.08
F1SK70 PROS1 Vitamin K-dependent protein S
isoform 2 preproprotein
27.9 ± 0.1 28.0 ± 0.0 28.2 ± 0.1 0.97 0.66 0.99 −0.05 0.06
F2Z5E2 SERPINC1 Antithrombin III 31.7 ± 0.1 31.7 ± 0.1 31.9 ± 0.1 0.97 0.96 0.99 −0.13 <0.01
ACUTE PHASE RESPONSE
F1RG45 AGT Angiotensinogen preproprotein 29.2 ± 0.2 29.4 ± 0.2 29.5 ± 0.2 0.77 0.08 0.99 0.32 <0.01
FETUA AHSG A-2-HS-glycoprotein 34.4 ± 0.3 33.8 ± 0.4 34.2 ± 0.4 0.57 0.30 0.99 −0.53 0.01
ALBU ALB Serum albumin 34.9 ± 0.2 34.5 ± 0.2 34.9 ± 0.2 0.28 0.35 0.99 −0.30 <0.01
AMBP AMBP Protein AMBP 28.4 ± 0.2 27.8 ± 0.2 28.4 ± 0.2 0.13 0.62 0.99 −0.20 0.03
(Continued)
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TABLE 2 | Continued
Uniprot ID Gene Protein Abundancea by treatment q-value NEC severity
CON PAR ENT PAR- CON ENT- CON ENT- PAR Coefficientb q-value
F1SKB1 CP Ceruloplasmin 30.2 ± 0.2 29.5 ± 0.1 29.5 ± 0.1 0.13 0.35 0.99 0.12 0.07
F1S8V7 CPN1 Carboxypeptidase N catalytic
chain
25.7 ± 0.2 25.6 ± 0.1 25.7 ± 0.2 0.80 0.98 0.99 −0.11 0.09
F1SH96 ITIH1 Inter-α-trypsin inhibitor heavy
chain H1
28.2 ± 0.1 28.2 ± 0.1 28.6 ± 0.1 0.97 0.98 0.99 −0.18 <0.01
ITIH1 ITIH1 Inter-α-trypsin inhibitor heavy
chain H1
29.0 ± 0.2 28.6 ± 0.2 29.1 ± 0.1 0.13 0.30 0.99 −0.24 <0.01
ITIH2 ITIH2 Inter-α-trypsin inhibitor heavy
chain H2
31.1 ± 0.1 31.1 ± 0.1 31.4 ± 0.1 0.97 0.98 0.99 −0.17 <0.01
F1SH92 ITIH4 Inter-α-trypsin inhibitor heavy
chain H4
31.9 ± 0.2 31.6 ± 0.1 31.5 ± 0.1 0.76 0.98 0.99 0.12 0.03
I3L5U6 LBP Lipopolysaccharide binding
protein
25.5 ± 0.2 24.8 ± 0.2 24.7 ± 0.2 0.68 0.98 0.99 0.21 0.02
F1SN68 ORM1 A-1-acid glycoprotein 34.9 ± 0.1 34.8 ± 0.1 34.9 ± 0.1 0.97 0.83 0.99 −0.09 0.05
Q9GMA6 SERPINA3-2 A-1-antichymotrypsin 2 30.5 ± 0.2 30.9 ± 0.2 30.7 ± 0.2 0.41 0.17 0.99 0.28 <0.01
TRFE TF Serotransferrin 34.4 ± 0.2 34.3 ± 0.1 34.5 ± 0.2 0.97 0.98 0.99 −0.16 0.06
COMPLEMENT SYSTEM
F1SLV6 MASP1 Complement component
MASP3
26.4 ± 0.2 26.0 ± 0.1 26.2 ± 0.2 0.47 0.31 0.99 −0.17 0.03
F1RQW7 C1R Complement c1r 23.4 ± 0.3 22.9 ± 0.3 22.3 ± 0.2 0.97 0.98 0.99 0.37 <0.01
F1SBS4 C2 Complement C2 24.8 ± 0.7 25.5 ± 0.5 25.2 ± 0.6 0.82 0.35 0.99 0.71 0.01
I3LTB8 C3 Complement C3 26.1 ± 0.7 25.2 ± 0.9 24.2 ± 0.9 0.97 0.98 0.99 0.86 0.03
F1RQW2 C3 Complement C3 30.7 ± 0.1 30.5 ± 0.1 30.5 ± 0.1 0.71 0.43 0.99 −0.09 0.10
F1SME1 C4A Complement C4-A isoform 1
preproprotein
28.2 ± 0.1 28.0 ± 0.2 27.9 ± 0.2 0.97 0.96 0.99 0.23 <0.01
F1SMI8 C5 Complement C5a anaphylatoxin 21.9 ± 0.5 20.6 ± 0.5 20.5 ± 0.4 0.97 0.98 0.99 0.48 0.01
F1S788 C6 Complement C6 26.3 ± 0.1 26.6 ± 0.1 26.7 ± 0.1 0.97 0.98 0.99 −0.18 <0.01
F1S790 C8A Complement C8 α chain 26.9 ± 0.1 26.8 ± 0.1 27.2 ± 0.1 0.73 0.98 0.99 −0.16 <0.01
A0SEH3 C8B Complement C8 β chain 25.8 ± 0.1 25.6 ± 0.1 25.7 ± 0.1 0.51 0.31 0.99 −0.15 0.01
F1S0J0 C8G Complement component C8G 22.4 ± 0.1 22.5 ± 0.1 22.5 ± 0.1 0.97 0.98 0.99 −0.13 0.03
F1S133 CD55 Complement decay-accelerating
factor
28.1 ± 0.1 27.9 ± 0.1 28.3 ± 0.1 0.86 0.39 0.06 0.05 0.10
D5L7X4 CFI Complement factor I 22.4 ± 0.2 22.6 ± 0.2 23.0 ± 0.2 0.97 0.98 0.99 −0.18 0.09
F1SJW8 SERPING1 Plasma protease C1 inhibitor 29.3 ± 0.3 29.8 ± 0.2 29.7 ± 0.2 0.45 0.21 0.99 0.28 0.01
INNATE IMMUNITY
F1SGT4 CD44 CD44 molecule 25.2 ± 0.1 25.2 ± 0.2 25.3 ± 0.2 0.97 0.84 0.99 −0.18 0.01
OSTP SPP1 Osteopontin 24.3 ± 0.2 24.4 ± 0.2 24.2 ± 0.2 0.97 0.97 0.99 0.21 0.04
CYTOSKELETON
I3L6D7 DSG2 Desmoglein 2 21.7 ± 0.3 21.9 ± 0.2 21.8 ± 0.3 0.95 0.46 <0.01 0.28 0.02
GELS GSN Gelsolin 29.7 ± 0.2 29.8 ± 0.2 30.0 ± 0.1 0.97 0.98 0.99 −0.20 0.01
F1RK02 LCP1 Lymphocyte cytosolic protein 1 22.3 ± 0.2 22.5 ± 0.2 22.5 ± 0.2 0.97 0.48 0.99 0.17 0.08
F1RFY1 PFN1 Profilin 21.9 ± 0.2 21.9 ± 0.3 21.6 ± 0.3 0.97 0.98 0.99 0.28 0.01
OTHERS
F1RUM1 AFM Afamin 28.8 ± 0.1 28.6 ± 0.1 28.8 ± 0.1 0.63 0.51 0.99 −0.17 0.01
FETA AFP A-fetoprotein 34.2 ± 0.1 34.0 ± 0.1 34.2 ± 0.1 0.35 0.51 0.99 −0.08 0.06
AMPN ANPEP Aminopeptidase N 21.6 ± 0.3 21.9 ± 0.2 21.9 ± 0.2 0.89 0.24 0.99 0.27 0.01
F1SBE4 B4GALT5 β-1,4-galactosyltransferase 5 23.0 ± 0.1 23.2 ± 0.1 23.2 ± 0.1 0.45 0.21 0.99 0.12 0.02
B9UJD6 C1QTNF3 C1q and tumor necrosis factor
related protein 3 isoform b
22.0 ± 0.1 22.0 ± 0.2 22.2 ± 0.2 0.97 0.97 0.99 −0.24 0.01
I3LRD3 CENPE Kinesin-like protein 24.8 ± 0.3 24.7 ± 0.3 25.1 ± 0.3 0.97 0.98 0.99 −0.27 0.08
F1SC70 CTSA Carboxypeptidase 23.2 ± 0.1 23.3 ± 0.2 23.7 ± 0.2 0.97 0.17 0.99 0.11 0.09
(Continued)
Frontiers in Immunology | www.frontiersin.org 8 October 2020 | Volume 11 | Article 565862
Jiang et al. Early Protein Markers of Necrotizing Enterocolitis
TABLE 2 | Continued
Uniprot ID Gene Protein Abundancea by treatment q-value NEC severity
CON PAR ENT PAR- CON ENT- CON ENT- PAR Coefficientb q-value
F1SPE9 DNAJC13 Dnaj heat shock protein family
(Hsp40) member C13
27.5 ± 0.3 27.9 ± 0.3 27.9 ± 0.3 0.76 0.21 0.99 0.40 0.01
I3LK59 ENO1 A-enolase isoform 1 21.7 ± 0.4 21.7 ± 0.5 21.7 ± 0.4 0.97 0.96 0.99 0.38 0.07
F1S715 FUCA2 A-L-fucosidase 25.1 ± 0.2 25.2 ± 0.2 25.6 ± 0.1 0.97 0.17 0.99 0.11 0.09
I3LN42 GC Vitamin D-binding protein 32.0 ± 0.1 32.0 ± 0.1 32.1 ± 0.1 0.97 0.76 0.99 −0.13 0.02
F1S4I1 GOLM1 Golgi membrane protein 1 24.9 ± 0.4 25.0 ± 0.5 24.4 ± 0.3 0.97 0.98 0.99 0.41 0.03
GPX5 GPX5 Epididymal secretory glutathione
peroxidase
25.3 ± 0.2 25.3 ± 0.1 25.6 ± 0.1 0.97 0.98 0.99 −0.17 0.03
F1SBR6 HIPK1 Homeodomain interacting
protein kinase 1
22.3 ± 0.1 22.4 ± 0.1 22.5 ± 0.2 0.97 0.98 0.99 −0.13 0.05
F1SJL1 IGDCC4 Immunoglobulin superfamily
DCC subclass member 4
22.4 ± 0.2 22.7 ± 0.1 22.6 ± 0.1 0.97 0.98 0.99 −0.18 0.01
F1SCC6 LOC100153899 Serpin A3-8 32.3 ± 0.3 31.1 ± 0.3 30.6 ± 0.3 0.48 0.89 0.99 0.46 <0.01
F1SCD0 LOC100153899 Serpin A3-8 32.9 ± 0.2 33.2 ± 0.2 33.2 ± 0.1 0.45 0.06 0.99 0.23 <0.01
F1SCC9 LOC106504545 Serpin A3-8 29.7 ± 0.4 30.4 ± 0.2 30.3 ± 0.2 0.97 0.98 0.99 −0.33 0.01
F1SCC7 LOC396684 Serpin A3-5 31.5 ± 0.2 31.2 ± 0.2 31.0 ± 0.2 0.97 0.98 0.99 0.33 <0.01
F1RLC4 LOX Protein-lysine 6-oxidase 23.4 ± 0.1 23.5 ± 0.1 23.5 ± 0.1 0.97 0.89 0.99 0.10 0.07
F1S7K2 LRG1 Leucine rich α-2-glycoprotein 1 27.0 ± 0.2 26.6 ± 0.2 26.5 ± 0.2 0.97 0.98 0.99 0.25 <0.01
I3L5Z3 PRG4 Proteoglycan 4 23.4 ± 0.5 22.7 ± 0.4 22.4 ± 0.3 0.97 0.98 0.99 0.36 0.06
F1SGH0 PTPRG Protein tyrosine phosphatase,
receptor type G
22.5 ± 0.4 23.3 ± 0.3 22.4 ± 0.5 0.41 0.76 0.99 0.46 0.01
F1SCD1 SERPINA3-2 A-1-antichymotrypsin 2 27.0 ± 0.7 26.3 ± 0.6 26.6 ± 0.6 0.97 0.65 0.99 −0.61 0.06
TFR1 TFRC Transferrin receptor protein 1 23.6 ± 0.3 23.9 ± 0.3 24.0 ± 0.3 0.90 0.30 0.99 0.35 0.01
aData are 2-based logarithm transformed and shown as mean ± SEM. CON, no antibiotic treatment; PAR, parenteral antibiotics administered; ENT, enteral antibiotics administered.
bRegression coefficient from the linear mixed-effect model indicating the effect of NEC severity.
FIGURE 2 | Summary of proteins with abundance changing with NEC severity. Proteins with increasing abundance are in red, decreasing ones in green.
and TIMP-1,−2, facilitates the recruitment of immune cells to
cross the endothelial and epithelial layers and reach the infection
sites. However, inflammation associated with systemic infection
and NEC alters the expression of ECM proteins in other organs,
too. Similar transcriptional changes of the above proteins have
been found in septic rats (32). Thus, it is difficult to attribute
changes in such plasma proteins found here to any specific organ
due to the ubiquitous expression of these proteins. They may
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FIGURE 3 | Correlation map of detected plasma proteins with differential abundance with NEC severity. The nodes in red are proteins with increasing abundance with
NEC severity, while those in blue are with decreasing abundance. The size of the nodes indicates the q-value of the effect of NEC severity reversely, i.e., the larger the
node, the smaller the q-value. The edge (line) in red shows a positive correlation between the two proteins, while those in blue show negative correlation. The width of
the edge shows the absolute value of the Spearman’s r. All correlations listed here are with Spearman’s r ≥ 0.7. Refer to Table 2 for full protein names.
also show an age-related regulation as elevated (not reduced)
serum levels of MMP-9 and TIMP-1, as well as reduced MMP-
9/TIMP-1 ratio, were observed in adult sepsis (33). While these
plasma proteins are of use in early NEC detection, more research
is clearly required to examine their utility in differentiating NEC
from sepsis.
Altered lipid metabolism and lipoprotein composition are
notable in adult infection and inflammation (34), and in
neonatal sepsis (35). In neonatal sepsis, plasma levels of
total cholesterol, total triglyceride, lipoprotein-a, high-density
lipoprotein (HDL), and apolipoprotein A and B are generally
reduced, relative to healthy controls (35). HDL composition
changes in endotoxemia, and levels of apolipoproteins, such
as the main HDL apolipoproteins, apo-A1 and A2, change
(35). Similar to the reduced level of ApoA1 and A2 reported
in sepsis, plasma levels of ApoC2, C3, and ApoD decreased
with increasing NEC severity. A decreased level of PON1, a
hydrolytic enzyme associated with HDL (36), was also observed,
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FIGURE 4 | Transcription in the liver of selected genes, (A) PON1, (B) PSCK9, (C) HRG, and (D) PROS1. NEC score: 1–2, no-NEC; 3–4, mild NEC; 5–6, severe NEC.
Data are presented as mean ± SEM. *P < 0.05.
in agreement with a previous report of infected humans (37).
PCKS9, binding to LDLR on the liver and increasing the LDL
levels in the circulation (38), decreased in abundance when
NEC progressed. Platelet-activating factor acetylhydrolase (PAF-
AH) degrades PAF, which is involved in NEC pathogenesis (39).
In line with our findings, a lower plasma level of PAF-AH
was found in NEC patients (40) and endotoxemic rats (39),
while increasing activity of plasma PAF-AH or oral feeding
of exogenous PAF-AH protects against NEC (41). Combined,
these findings suggest a perturbed lipid metabolism during NEC,
either as a cause or a consequence of NEC. However, levels
of lipoproteins and other lipid metabolism-related parameters
are affected by the regimen of parenteral nutrition. Unlike
our pigs, which received parenteral nutrition with identical
regimens, regimens of parenteral nutrition for human patients
vary profoundly among patients and among clinics, thus the
utility of lipid metabolism-related plasma proteins as markers of
human NEC requires further investigation.
Coagulopathy, a common systemic feature of NEC (42), is
characterized by enhanced coagulation and impaired fibrinolysis
(43). Among the proteins observed in this study, antithrombin
III from the liver inactivates thrombin and coagulant factors,
while PROS1 inhibits coagulation as a cofactor in the inactivation
of Factors Va and VIIIa (44). Similar to our findings in NEC,
plasma levels of antithrombin III and PROS1 decreased in
septic neonates (45). Decreased plasma levels of these two
proteins, together with increased levels of fibrinogen-α-chain,
may reflect enhanced coagulation in NEC. However, Factor V
involved in coagulation showed decreasing abundance, while
HABP2, enhancing fibrinolysis, increased moderately with NEC
progression. HRG showed an increasing plasma level as NEC
increased, but it reportedly decreased in septic mice (46). Some of
these affected proteins changed in a different direction for NEC
and sepsis (e.g., HRG), but more studies are required to identify
NEC- and sepsis-specific biomarkers.
Multiple acute phase proteins, including complement
components, were affected by NEC, and in prospective infant
studies, plasma inter-α-trypsin inhibitor levels decreased in NEC
patients (47). In this study, ITIH1 and ITIH2 (two heavy chains
of inter-α-trypsin inhibitor) decreased in abundance, while
ITIH4 increased. Most “positive” acute phase proteins increase
when NEC progresses, while several “negative” regulators
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FIGURE 5 | Plasma abundance and transcription levels in the liver of CBG by the antibiotic treatment group (A,B) and by the presence of NEC (C,D). Data are
presented as mean ± SEM. *P < 0.05. CON, no antibiotic treatment; PAR, parenteral antibiotics administered; ENT, enteral antibiotics administered.
decrease. Detected complement proteins include components
from all three major pathways, namely, the classical, alternative,
and lectin pathways, and components of the early (C1q, C2,
C4a, MASP1), middle (C3, C5a), and late (C6, C8) complement
response, together with a receptor (CR1) and inhibitors (CFI,
CD55). Among these proteins, AHSG, C3, and C5 were found
with a relatively large regression coefficient of NEC. Combined,
the complement response, such as increased abundance of
C2, C3, C5a, decreased negative regulators, CR1 and CD55,
suggests a possibility to detect the early NEC by changes in
the complement cascade. A comprehensive study is required
to investigate the actions of the complement system in NEC
progression to ascertain any potential utility in NEC prediction
or detection. Besides, more research is required to show if they
are indeed among the earliest systemic signs of NEC progression,
when clinical signs are unclear.
Besides the effect to kill or suppress microbes, antibiotics
may have both local and systemic anti-inflammatory and
vasomodulatory effects (6, 48). Our analyses showed that
antibiotics altered blood hematology and biochemistry, such
as monocyte counts and albumin levels, with similar effects
from the two administration routes (PAR or ENT). Multiple
proteins were affected by the antibiotic treatment alone, although
corticosteroid-binding globulin (CBG) was also affected by NEC.
Levels of CBG, the main cortisol-transporting protein in plasma,
decreased during infection and sepsis (49). Lower plasma levels
of CBG were found by us in preterm piglets with sepsis (50). In
contrast, NEC lesions had limited effect on plasma CBG levels
in this study. Similar trends of change at transcription level were
found in the liver of these pigs, suggesting that at least part of
the systemic CBG change in this study originated from liver
effects. The proteomic analyzing technology adopted here can
only detect the level of total CBG with no differentiation of
the high- or low-affinity types. It is of interest to determine the
NEC-related plasma level of high-affinity CBG (haCBG), and its
relation to cortisol, as bioactive glucocorticoid levels may play a
role in NEC progression and repair.
CONCLUSION
In preterm pigs, presence of NEC lesions was associated with
numerous systemic plasma protein effects that may be the
targets for developing new early biomarkers of NEC. Proteins
with large NEC-related changes in abundance (large regression
coefficient) were RBP4, FGA, AHSG, C3, C4A, PTPRG, and α-
1-antichymotrypsin 2. More research is required to verify their
Frontiers in Immunology | www.frontiersin.org 12 October 2020 | Volume 11 | Article 565862
Jiang et al. Early Protein Markers of Necrotizing Enterocolitis
possible utility in indicating NEC in clinical conditions with
varying gestational age, antibiotics usage, and feeding regimen,
and in differentiating NEC from the conditions inducing
systemic effects, but not related to gut complications, including
bacteremia and sepsis.
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